Compare Abeona Therapeutics Inc (ABEO) vs The Vita Coco Company Inc (COCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs The Vita Coco Company Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while The Vita Coco Company Inc trades at $66.7 (market cap $3.74B). The key difference: The Vita Coco Company Inc is far larger — about 10× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, The Vita Coco Company Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | COCO | |
|---|---|---|
Market Cap | $373.32M | $3.74B |
Sector | Health | Technology |
52-Week High | $7.23 | $84.02 |
52-Week Low | $4.17 | $32.30 |
Enterprise Value | $228.22M | $3.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
COCO trades at $66.78, up 0.94% today, with a bullish technical signal driven by oversold RSI readings but bearish moving averages. The company reported strong Q1 2026 EPS of $0.50, beating expectations, and shows robust profitability with a 12.59% net margin and 26.32% ROE. Recent news highlights market dominance in coconut water and expanded partnerships, supporting growth prospects amid a $125 billion market opportunity.
Outlook is positive with a consensus price target of $79.33, implying 19% upside, though high valuation multiples (P/E 48.39) and competitive pressures pose risks. Investors should weigh strong earnings momentum against potential volatility from sector rotation and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →
